Phase II multicenter study of carfilzomib, lenalidomide, and dexamethaxone (KRd) as induction, followed by high-dose melphalan and autologous peripheral blood progenitor cell transplantation, consolidation with KRd and maintenance with lenalidomide and dexamethasone in patients under 65 years of age with Asymptomatic multiple myeloma with high risk of progression to symptomatic myeloma
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: PETHEMA FOUNDATION
- Phase: II
- Execution start: 03/02/2016
- End of execution: 28/02/2020
- IP: